Kyntra Bio Inc (KYNB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.55+0.71%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KYNB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -35.1% |
| Our one-year growth estimate | diamond | 30.0% |
Growth built into the price is above our model estimate.
The price assumes 65.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
KYNB — capital allocation
Dated 2026-08-31
in its entirety. As previously disclosed, the Company’s subsidiary, FibroGen Europe, voluntarily submitted for bankruptcy to the Finnish bankruptcy court in April 2026. Taken together, the A&R RIFA and the FibroGen Europe bankruptcy have reduced the Company’s future liabilities by approximately $80 million.
Why it matters: Lowering operating losses is key for Kyntra's finances. Better results mean better cost control.
Supportive ifOperating losses decrease from -$15.1 million in Q1 2026 to below -$13 million in Q2 2026.
Worry ifOperating losses go up or stay over -$15 million in Q2 2026.
Why it matters: Cash reserves are important for funding operations. A big drop could mean trouble.
Worry ifCash and equivalents are over $90 million. This shows strong liquidity.
Less concerning ifCash and equivalents are below $90 million. This raises concerns about funding.
Why it matters: Starting this trial is a key step for Kyntra Bio's growth in treating anemia in LR-MDS. It shows progress in their pipeline.
Supportive ifThe company announces the start of the Phase 3 trial for roxadustat.
Worry ifThe company delays the trial initiation or fails to provide a clear timeline.
Why it matters: If healthcare sector revenue growth speeds up, it could benefit Kyntra Bio. This would show a healthier market for its products.
Supportive ifHealthcare sector revenue growth is speeding up again. It is moving toward 10% or more.
Worry ifHealthcare sector revenue growth continues to slow or stays below 10%.
Why it matters: Revenue growth is key to Kyntra Bio's financial health. Sustained growth signals a positive trajectory.
Supportive ifRevenue goes up year over year, showing strong business performance.
Worry ifRevenue goes down or stays the same, suggesting problems in business operations.
Why it matters: Kyntra needs steady revenue growth for long-term success. It shows that the market accepts its products.
Supportive ifRevenue growth continues to exceed 10% quarter over quarter.
Worry ifRevenue growth falls below 5% quarter over quarter.
Why it matters: Updates on cash runway help us understand Kyntra's financial health. It affects funding.
Watch forManagement says cash runway lasts until 2028 without needing more funding.
Also watch forManagement warns they may need more funding before 2028.
Why it matters: Earnings results will show Kyntra Bio's financial health and how well it operates. They can affect investor feelings.
Watch forQ2 earnings report shows good results, which means strong performance.
Also watch forQ2 earnings report shows a miss similar to the recent earnings miss on May 11.
Why it matters: Another earnings miss would show ongoing money problems. This could hurt investor trust and stock value.
Worry ifQ2 earnings miss reported on August 10, 2026.
Less concerning ifQ2 earnings meet or exceed expectations on August 10, 2026.
Why it matters: Continued revenue growth is crucial for Kyntra's financial health. It reflects the market acceptance of their products.
Supportive ifRevenue for Q3 2026 shows an increase compared to Q2 2026.
Worry ifQ3 2026 revenue declines compared to Q2 2026.
Why it matters: Good interim results may increase trust in Kyntra's cancer treatments and stock.
Supportive ifInterim results from the Phase 2 trial of FG-3246 are reported as positive.
Worry ifInterim results from the Phase 2 trial of FG-3246 are disappointing or delayed.
Why it matters: Starting this trial is key for Kyntra's growth in treating lower-risk MDS.
Supportive ifKyntra starts the Phase 3 trial for roxadustat.
Worry ifKyntra delays the initiation of the Phase 3 trial for roxadustat.
Why it matters: Updates on cash will show Kyntra's ability to pay for operations and trials.
Watch forKyntra says cash runway goes into 2028.
Also watch forKyntra shortens its cash runway guidance.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$143 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $466 loss on $10,000 · 4.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,803 loss on $10,000 · 48.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.